Roche's Gazyva Breaks New Ground in Lupus
Roche's Gazyva, already approved for kidney damage in lupus, may be heading for broader use in the autoimmune disorder.
Gazyva, an anti-CD20 antibody, showed promise in the phase 3 ALLEGORY trial for systemic lupus erythematosus (SLE), affecting around 3.4 million people worldwide.
- Gazyva achieved its main objective in ALLEGORY, increasing the proportion of patients showing improvement on the SLE Responder Index 4 (SRI-4) scale at 52 weeks.
- The drug was compared to placebo, with standard therapy added.
No direct quotes available in the text.
Author's summary: Gazyva has potential for broader use in lupus treatment.